Page 73 - Read Online

Fonseca et al. Hepatoma Res 2023;9:27 https://dx.doi.org/10.20517/2394-5079.2023.63 Page 5 of 5

Consent for publication
Not applicable.

Copyright
© The Author(s) 2023.

REFERENCES
1. Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol
2022;76:681-93. DOI PubMed PMC
2. da Fonseca LG, Marta GN, Braghiroli MIFM, et al. Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after
first-line treatment with sorafenib. BMC Cancer 2018;18:1250. DOI PubMed PMC
3. Nault JC, Martin Y, Caruso S, et al. Clinical impact of genomic diversity from early to advanced hepatocellular carcinoma. Hepatology
2020;71:164-82. DOI
4. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34. DOI
5. Llovet JM, Ricci S, Mazzaferro V, et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med 2008;359:378-90. DOI
6. Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment
(RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389:56-66. DOI
7. Finn RS, Merle P, Granito A, et al. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional
analyses from the phase III RESORCE trial. J Hepatol 2018;69:353-8. DOI
8. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular
carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391:1163-73. DOI
9. Abou-Alfa GK, Meyer T, Cheng A-L, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl
J Med 2018;379:54-63. DOI PubMed PMC
10. Zhu AX, Kang YK, Yen CJ, et al; REACH-2 study investigators. Ramucirumab after sorafenib in patients with advanced
hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled,
phase 3 trial. Lancet Oncol 2019;20:282-96. DOI
11. Ramadori G, Füzesi L, Grabbe E, Pieler T, Armbrust T. Successful treatment of hepatocellular carcinoma with the tyrosine kinase
inhibitor imatinib in a patient with liver cirrhosis. Anticancer Drugs 2004;15:405-9. DOI
12. Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib
for unresectable hepatocellular carcinoma. J Hepatol 2022;76:862-73. DOI PubMed PMC
13. Abou-alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evidence
2022:1. DOI
14. Singal AG, Llovet JM, Yarchoan M, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular
carcinoma. Hepatology 2023. DOI
15. D'Alessio A, Fulgenzi CAM, Nishida N, et al. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in
patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study. Hepatology 2022;76:1000-12. DOI
16. El Hajra I, Sanduzzi-Zamparelli M, Sapena V, et al. Outcome of patients with HCC and liver dysfunction under immunotherapy: a
systematic review and meta-analysis. Hepatology 2023;77:1139-49. DOI
17. Marrero JA, Kudo M, Venook AP, et al. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: the
GIDEON study. J Hepatol 2016;65:1140-7. DOI
18. Daniele G, Schettino C, Arenare L, et al. BOOST: a phase 3 trial of sorafenib vs. best supportive care in first line treatment of
hepatocellular carcinoma in patients with deteriorated liver function. Hepatoma Res 2021;7:61. DOI
19. Anugwom CM, Leventhal TM, Debes JD. Understanding immune perspectives and options for the use of checkpoint immunotherapy
in HCC post liver transplant. Hepatoma Res 2022;8:7. DOI PubMed PMC
20. Hack SP, Spahn J, Chen M, et al. IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular
carcinoma after curative resection or ablation. Future Oncol 2020;16:975-89. DOI PubMed
21. Kudo M, Ueshima K, Chan S, et al. Lenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma
beyond up-to-seven criteria and child-pugh a liver function: a proof-of-concept study. Cancers 2019;11:1084. DOI PubMed PMC